We are live on
!
Find out more
CM
Crestline Management Portfolio holdings
AUM
$46.3M
1-Year Est. Return
48.82%
This Fund
S&P 500
This Quarter
Est. Return
-6.42%
1 Year Est. Return
+48.82%
3 Year Est. Return
+52.52%
5 Year Est. Return
+37.91%
10 Year Est. Return
+316.44%
AUM
$976M
AUM Growth
+$257M
(+36%)
Cap. Flow
+$279M
Cap. Flow
% of AUM
28.55%
Top 10 Holdings %
Top 10 Hldgs %
76.43%
Holding
234
New
114
Increased
26
Reduced
16
Closed
77
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Denali Therapeutics
DNLI
|
+$370M |
| 2 |
American International
AIG
|
+$8.49M |
| 3 |
Ameriprise Financial
AMP
|
+$7.55M |
| 4 |
T. Rowe Price
TROW
|
+$7.55M |
| 5 |
Visa
V
|
+$6.43M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
JUNO
Juno Therapeutics, Inc.
JUNO
|
+$85.7M |
| 2 |
FNB Corp
FNB
|
+$8.22M |
| 3 |
Travelers Companies
TRV
|
+$7.78M |
| 4 |
Sherwin-Williams
SHW
|
+$7.34M |
| 5 |
Willis Towers Watson
WTW
|
+$7.28M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 37.59% |
| 2 | Financials | 12.34% |
| 3 | Technology | 4.43% |
| 4 | Industrials | 4.41% |
| 5 | Consumer Discretionary | 1.16% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
GRA
101
DELISTED
W.R. Grace & Co.
GRA
| $1.1M | 0.11% |
15,751
-49,249
| -76% | -$3.57M |
|
102
FTI Consulting
FCN
$4.4B
| $1.08M | 0.11% |
25,107
+789
| +3% | +$32.2K |
|
103
Sony
SONY
$137B
| $1.08M | 0.11% |
+120,000
| New | +$1.03M |
|
104
CNO Financial Group
CNO
$5.14B
| $1.06M | 0.11% |
43,004
+8,853
| +26% | +$216K |
|
|
CTXS
105
DELISTED
Citrix Systems Inc
CTXS
| $1.06M | 0.11% |
+12,000
| New | +$1.02M |
|
|
CPRX
106
DELISTED
Catalyst Pharmaceutical
CPRX
| $1.04M | 0.11% |
267,112
+44,093
| +20% | +$146K |
|
|
FOMX
107
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
| $1.04M | 0.11% |
173,501
| – | – |
|
|
SWIR
108
DELISTED
Sierra Wireless
SWIR
| $1.02M | 0.1% |
+50,039
| New | +$1.07M |
|
109
Energy Recovery
ERII
$446M
| $1.02M | 0.1% |
+116,121
| New | +$1.06M |
|
|
CA
110
DELISTED
CA, Inc.
CA
| $1.01M | 0.1% |
+30,360
| New | +$1.01M |
|
111
Skyworks Solutions
SWKS
$9.37B
| $992K | 0.1% |
+10,452
| New | +$1.09M |
|
112
Kulicke & Soffa
KLIC
$4.67B
| $973K | 0.1% |
+40,000
| New | +$954K |
|
113
AT&T
T
$159B
| $972K | 0.1% |
+33,100
| New | +$904K |
|
114
Astec Industries
ASTE
$1.16B
| $952K | 0.1% |
+16,274
| New | +$873K |
|
|
GCP
115
DELISTED
GCP Applied Technologies Inc.
GCP
| $952K | 0.1% |
+29,853
| New | +$918K |
|
|
SRCL
116
DELISTED
Stericycle Inc
SRCL
| $936K | 0.1% |
+13,761
| New | +$934K |
|
|
CNR
117
DELISTED
Cornerstone Building Brands, Inc.
CNR
| $894K | 0.09% |
+46,303
| New | +$779K |
|
|
AXE
118
DELISTED
Anixter International Inc
AXE
| $831K | 0.09% |
+10,935
| New | +$805K |
|
|
GLDD
119
DELISTED
Great Lakes Dredge & Dock
GLDD
| $775K | 0.08% |
+143,435
| New | +$730K |
|
|
USG
120
DELISTED
Usg
USG
| $773K | 0.08% |
+20,053
| New | +$704K |
|
121
Hexcel
HXL
$7.79B
| $757K | 0.08% |
12,243
-37,757
| -76% | -$2.3M |
|
|
OMED
122
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
| $753K | 0.08% |
+183,687
| New | +$799K |
|
123
Varonis Systems
VRNS
$4.59B
| $752K | 0.08% |
+46,455
| New | +$729K |
|
124
SEI Investments
SEIC
$12.4B
| $743K | 0.08% |
+10,345
| New | +$693K |
|
125
Celestica
CLS
$38.1B
| $734K | 0.08% |
+70,000
| New | +$774K |
|
Similar funds
MCMC
RRC
PCM
NPCM
FCM
EGI
IPHI
SM
Crestline Management's Q4 2017 Portfolio in Review
As of Q4 2017, Crestline Management held 234 positions worth $976M, up 36% from $719M the previous quarter. Its ten largest holdings account for 76% of the portfolio.
Crestline Management deployed $279M of net new capital in Q4 2017, opening 114 new positions and adding to 26 existing holdings. Its largest new stake was Denali Therapeutics: 20,574,298 shares worth $322M.
By sector, the portfolio is most concentrated in Healthcare at 38% of assets, up from 5.7% a quarter earlier, followed by Financials and Technology.
On the sell side, the largest reduction was Juno Therapeutics, Inc., an estimated $85.7M trimmed.
- Crestline Management's largest Q4 2017 buy was Denali Therapeutics: 20,574,298 shares worth $322M.
- Crestline Management added most to Ameriprise Financial in Q4 2017, an estimated $7.55M increase.
- Crestline Management's biggest Q4 2017 reduction was Juno Therapeutics, Inc., cutting an estimated $85.7M.
- Crestline Management fully exited FNB Corp in Q4 2017, selling an estimated $8.22M.
- Crestline Management's ten largest holdings make up 76% of its $976M portfolio in Q4 2017.
- Crestline Management opened 114 new positions and closed 77 in Q4 2017.
- Crestline Management's portfolio value rose 36% quarter-over-quarter to $976M.
Based on Crestline Management's 13F filing for Q4 2017, filed 14 Feb 2018.